Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib mesylate versus allogeneic HSCT for patients with chronic myelogenous leukemia
ChiCTR-TNC-10000955Phase 4Completed
- Sponsor
- Peking University People's Hospital
- Start
- Apr 2001
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of imatinib in chronic myelogenous leukemia (CML) (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: overall survival. Started Apr 2001; status: completed.
02
Drugs
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ChiCTR-TNC-10000955.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TNC-10000955.